PD-1 Monoclonal Antibody Camrelizumab Combined With Albumin Paclitaxel and Platinum for Neoadjuvant Treatment of Adcanced Esophageal Squamous Cell Carcinoma (ESCC): A Single-center, Single-arm Phase II Clinical Study
Latest Information Update: 06 Mar 2023
At a glance
- Drugs Camrelizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 02 Mar 2021 We have added stages III & IV as study title mentions "advanced".
- 01 Mar 2021 New trial record